Three of our portfolio companies (@CombatCancer @LightpointMed
and @entiahealth) named by Coutts as "#medtech marvels supporting the NHS"
Coutts backs med-tech marvels supporting NHS
Meet four of the firms forging the future of health care with help from our clients
www.coutts.com
To register for this Friday's webinar (5-6 UK) click on the Eventbrite link
#HIVEC #BCGUnresponsive
HIVEC for BCG Unresponsive
Find out more about HIVEC in BCG Unresponsive Patients with Clinical Discussion and Live Q&A. EAU20 Presented Data.
www.eventbrite.co.uk
Join us on Friday 4th September at 5pm to find out more about HIVEC in BCG Unresponsive patients
@cordekroon @HUReinaSofia @ESSOnews @operarelcancer @SWexner @DeliaCortesGuir @FarazKh65499316 @dr_mohammadyami @AndreasBrandl8 @annafagottimd Closed system with CO2 agitation system @CombatCancer @jansenaxel is an option for drug distribution
Join us on Friday 4th September at 5pm to find out more about HIVEC in BCG Unresponsive patients
#HIVEC #EAU20 Data presented at EAU20 shows HIVEC treated BCG unresponsive patients 54% RFS at 24 months. Complete Response Rate for BCG unresponsive CIS patients over 70% at 6 months. Contact us to find out more.
Just in case you missed this trial data presented at AUA20, #HIVEC immediately prior to TURBT shows equivalent recurrence to I-POP but with 100% adherence for HIVEC, 33% greater than for I-POP.https://bit.ly/3fjnHyD
https://laparoscopic-hipec-a-new-point-of-view.eventbrite.co.uk
@CombatCancer #HIPEC Don't forget to register to join Combat and Dr Alvaro-Arjona-Sanchez later today to find out more.
https://www.urotoday.com/conference-highlights/aua-2020/aua-2020-bladder-cancer/122466-aua-2020-bcg-vs-chemohyperthermia-with-mitomycin-c-for-high-risk-non-muscle-invasive-bladder-carcinoma-preliminary-results-of-hivec-hr-randomized-clinical-trial.html via @urotoday
Many thanks @urotoday for covering our trial data https://twitter.com/urotoday/status/1276923364402225152
#BCG vs chemohyperthermia with mitomycin C for high-risk #NMIBC. Preliminary results of HIVEC-HR randomized clinical trial presented by @DrFelixGuerrero @Urologia12. #AUAlive written coverage by @zklaassen_md @GACancerCenter on UroToday > https://bit.ly/384fw6I @AmerUrological
#HIPEC #Laparoscopic #SurgicalOncology @CombatCancer Join Combat and Consultant Surgeon Dr Alvaro-Arjona-Sanchez to find out more about Laparoscopic HIPEC experience and results. Register for online event https://laparoscopic-hipec-a-new-point-of-view.eventbrite.co.uk
Don't forget to register for tomorrow's clinical discussion on HIVEC-R, look forward to seeing you and sharing this data that was selected for AUA20 #HIVEC
Join @CombatCancer #HIVEC and Dr Alejandro Sousa for live clinical discussion and Q&A on HIVEC-R.
To register click https://combat-hivec.eventbrite.co.uk
Join @CombatCancer #HIVEC and Dr Alejandro Sousa for live clinical discussion and Q&A on HIVEC-R.
To register click https://combat-hivec.eventbrite.co.uk
@Yormigjgv @DrFelixGuerrero @smumexico @UroTratamiento @Urologia12 Webinar:
Inscripción
ID de reunión: 915 9289 1390
Welcome! You are invited to join a webinar: Evaluación Clínica de Quimioterapia Térmica para Cáncer de Vejiga: Ponencia AUA 2020. After registering, you will receive a confirmation email about joining the webinar.
Ponente: Dr. Felix Guerrero Títular de la Unidad de Uroncología del Hospital Universitario 12 de Octubre, Madrid, España. Jefe la Unidad de Cáncer...
zoom.us
@CombatCancer #HIVEC Neo-Adjuvant HIVEC shows over 60% complete response and better RFS in preliminary trial result. Abstract accepted for AUA20, follow link to see full abstract https://bit.ly/2W2bA1Q
There are some great posters @ #BLADDR18 #HIVEC pic.twitter.com/bDnahheB4s
— Combat Medical #HIVEC #HIPEC (@CombatCancer) September 20, 2018
